Dr. Laila Al-Haddad and Professor Haider Behbehani, faculty members in the Department of Chemistry at the College of Science, presented a scientific research paper in cooperation with a team in the field of cancer research, and it was published in an international scientific journal (Drug Delivery) Q1. The research team included Prof. Sadashiva Karnak from Cleveland Clinic – USA.
Cancer-targeted drug delivery using active low-density lipoprotein nanoparticles encapsulated pyrimidines heterocyclic anticancer agents as microtubule inhibitors

Laila Jaragh-Alhadad, Haider Behbehani & Sadashiva Karnik
The research team included Prof. Sadashiva Karnak from Cleveland Clinic – USA.
Prof. Haider Behbehani said that the idea of the research stemmed from the recent reliance of cancer medicine on medical nanotechnologies to increase the efficiency, speed, and effectiveness of drug access to the cancerous target.
Dr. Layla Al-Haddad used the idea of a Trojan horse that entered the fort as a gift loaded with soldiers, then the soldiers disembarked in the center of the fort and eliminated it. Accordingly, cyclic pyrimidine compounds were encapsulated in Cleveland laboratories in the United States of America with (LDL) nanoparticles and measured their stability and shape. Their bioefficiency on breast (MDA468) and prostate (DU145) cancer cells was also evaluated.
The research team concluded that (Nano LDL) mimics the metabolic pathway of natural (LDL) in the body, so that the human body's antibodies do not target it as a foreign compound, and the anti-cancer compound reaches the breast and prostate cancer cell and eliminates it.